 |
 |
-----Oorspronkelijk bericht----- Van: Ivan M Suzman <[log in to unmask]> Aan: [log in to unmask] <[log in to unmask]> Datum: maandag 31 januari 2000 13:02 Onderwerp: Re: CSR FEB 00/ Funds for" HDV", proposed PD-CAUSING virus >>Latchman D, Coffin R; Mov Disord 2000;15:9-17: They discuss the use and choice of different viral vectors for delivery of modified genes in treatment of PD. This topic interests me greatly. I wonder if the modified genes can be designed to compensate for the ravages caused by a PD-causing virus. Do they write about the CAUSE of PD, or only about delivery of PD-repairing viral vectors? << ========== Parkinson's disease is an obvious target for the development of gene therapy procedures which could involve both the delivery of the gene encoding tyrosine hydroxylase to boost dopamine production or the delivery of genes encoding neurotrophic factors such as GDNF to promote the survival of dopaminergic neurons. A variety of different viral and nonviral methods for achieving such gene delivery are described together with the particular advantages of herpes simplex virus-based vectors which have the potential to deliver multiple therapeutic genes in a single virus vector. ========== >> Does anyone on PIEN know these authors? << Latchman, Professor David MA, PhD, DSc, MRCPath Department of Molecular Pathology & Clinical Biochemistry, UCL Professor of Molecular Pathology/Director of Windeyer Institute/Head of Department gene regulation in neuronal cells and in the heart; transcription factors, gene therapy transcription; neurological disease; Brn-3; Parkinson’s disease; heat shock proteins [log in to unmask] Coffin, Dr Robert MSc, PhD Department of Molecular Pathology & Clinical Biochemistry, UCL Senior Research Fellow/Honorary Lecturer in Molecular Virology gene therapy; virology; herpes virus latency gene therapy; HSV; neurological disease [log in to unmask] >> Chaudhuri K et al; Mov Disord 2000;15:18-23: Ongoing study since 1995 shows, even after excluding multiple system atrophy (MSA) and progressive supranuclear palsy (PSP), that prevalence of atypical, sporadic, L-dopa-resistant PD is 3- to 4-fold greater among Afro-Caribbean or Indian immigrants to the UK than among the remainder population. is this discussed in a viral-origin, or only in genetic framework? << genetic Hans.